Hypoparathyroidism Management During Pregnancy and Breastfeeding

Dr. Lubitz explains that pregnancy significantly alters calcium physiology. PTHrP produced by the placenta and the lactating breast, combined with increased 1,25-dihydroxyvitamin D in the first trimester, can dramatically shift the doses of active vitamin D and calcium required. This variability is unpredictable—some patients need significantly higher doses during pregnancy while others need lower doses. Poor maternal calcium control carries serious risks including premature labor, premature rupture of membranes, preeclampsia, seizures, kidney stones, and arrhythmia. Fetal risks include low birth weight and fetal seizures. If maternal calcium is too high, the fetus may develop hypoparathyroidism; too low, the neonate risks hyperparathyroidism.

Current guidelines recommend checking calcium, magnesium, phosphorus, and renal function every two to four weeks throughout pregnancy, with additional checks within one week of any dose adjustment.

For preconception counseling, Dr. Lubitz emphasizes preparing patients for significant calcium fluctuations during pregnancy and breastfeeding, including the frequently overlooked transition point when breastfeeding ends—a time when calcium metabolism can shift abruptly. She notes that all women of childbearing age should be informed there are no safety data for PTH analogs in pregnancy or breastfeeding, and that guidelines recommend switching back to conventional therapy as part of preconception planning.

Dr. Cusano shares a case in which a patient planned to continue PTH 1–84 during a second pregnancy but was forced to transition mid-pregnancy due to a product recall, fortunately without safety concerns. Dr. Shoback confirms she has not yet used PTH analogs in pregnant patients. The panel agrees that real-world data from registries—including the Paradigm Registry and the Global Pregnancy Registry for palopegteriparatide—are urgently needed to guide clinical practice for this population.

In the next episode, "Hypoparathyroidism in Special Populations: Pediatric, Geriatric, and Comorbid Patients," Dr. Ferenczi outlines how hypoparathyroidism management must be adapted for children, older adults, and patients with renal impairment, malabsorption, cardiovascular disease, and other complex comorbidities.